Clinical trials: Percutaneous Coronary Intervention Patients
Coronary Artery Disease
STEEL Percutaneous Coronary Intervention
The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients…
- Trial name
- STEEL-PCI (NCT02327624)
- Testing
- Clopidogrel, Ticagrelor 60, Ticagrelor 90
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
CA-AKI - Contrast-Associated Acute Kidney Injury, Coronary Artery Disease
Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI
To evaluate the efficacy and safety of phentolamine in prevention of CA-AKI following complex PCI in patients at high risk of CA-AKI.
- Conditions
- CA-AKI - Contrast-Associated Acute Kidney Injury, Coronary Artery Disease, Acute Coronary Syndrome, Adrenergic Receptor Antagonist Adverse Reaction
- Trial name
- NCT06286059
- Testing
- Phentolamine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Helwan University
Acute Anterior Myocardial Infarction
Effects of Intensive Statin Treatment on Left Ventricular Function
First acute anterior myocardial infarction in patients with primary PCI preoperative and postoperative 30 days intensive dose atorvastatin statin therapy compared with conventional -dose therapy , patients can improve left…
- Trial name
- NCT01936103
- Testing
- standard group, intensive group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Northern Hospital
Acute Coronary Syndrome, High Bleeding Risk
LEADERS FREE II: BioFreedom™ Pivotal Study
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
- Trial name
- NCT02843633
- Testing
- BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 1,203 people
- Sponsor
- Biosensors Europe SA
Acute Coronary Syndrome
The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention
This is a multicenter, prospective, observational investigation, focusing of antiplatelet treatment in patients with moderate to high risk acute coronary syndrome (TIMI risk score ≥3)subjected to percutaneous coronary…
- Trial name
- GRAPE (NCT01774955)
- Where
- 9 sites in Greece
- Volunteers
- 2,047 people
- Sponsor
- University of Patras
ST Elevation Myocardial Infarction
Risk Characterization of Non-culprit Vessels in Patients Undergoing Primary PCI for ST-elevation MI in Multivessel Disease
Most heart attacks occur because a clot forms in a coronary artery blocking blood flow. Without blood heart muscle dies. Untreated, clots can cause a specific type of heart attack -ST-elevation myocardial infarction (STEMI).
- Trial name
- PICNIC (NCT06506448)
- Testing
- CT Coronary Angiography
- Where
- 3 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
ST Elevation Myocardial Infarction
Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay
The OPTIMAL-REPERFUSION trial will help determine whether reduced-dose facilitated PCI strategy improves clinical outcomes in patients with STEMI and anticipated PPCI delay
- Trial name
- NCT04752345
- Testing
- Pharmacoinvasive strategy, Reduced-dose facilitated PCI strategy
- Volunteers
- 632 people
- Sponsor
- West China Hospital
Acute Myocardial Infarction (AMI)
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
The goal of this clinical trial is to learn if drug tafolecimab works to treat participants with acute myocardial infarction (AMI) scheduled for primary percutaneous coronary intervention (PCI).
- Trial name
- IMPROVE-AMI (NCT06683131)
- Testing
- Tafolecimab
- Where
- 13 sites in China
- Volunteers
- 1,160 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Contrast Induced Nephropathy, Acute Myocardial Infarction
Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)
The purpose of this study is to determine the incidence of contrast induced nephropathy and myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide administration in patients with acute myocardial…
- Trial name
- CONTRAST-AMI (NCT00827788)
- Testing
- Iodixanol, Iopromide
- Where
- Italy
- Volunteers
- 432 people
- Sponsor
- Ospedale San Donato
Coronary Artery Disease
Physio PCI: Impact of Coronary Angioplasty on Non-hyperaemic Pressure Ratio in Patients With Coronary Artery Disease
The use of intra coronary physiological assessment with fractional flow reserve (FFR) is nowadays the standard approach to define ischemia-inducing stenosis and guide myocardial revascularization strategy in patients with…
- Trial name
- NCT04679805
- Where
- United Arab Emirates
- Volunteers
- 3 people
- Sponsor
- Ceric Sàrl
Atrial Fibrillation, Coronary Artery Disease
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
This study is to compare the efficacy and safety of dabigatran ethidium b.i.d.+ clopidogrel + ASA [100 mg q.d. *1 month] and warfarin + clopidogrel + ASA [100 mg, q.d.*1 month] in Chinese NVAF patients undergoing PCI with…
- Trial name
- COACH-AF-PCI (NCT03536611)
- Testing
- dabigatran, warfarin
- Where
- China
- Volunteers
- 1,120 people
- Sponsor
- Shenyang Northern Hospital
Percutaneous Coronary Intervention
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of…
- Trial name
- NCT00077844
- Testing
- Enoxaparin sodium
- Volunteers
- 3,532 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel Following PCI
Coronary artery disease occurs when the blood vessels supplying the heart become narrowed or blocked. Percutaneous coronary intervention (PCI) is a procedure used to restore blood flow to the heart, often by inserting a stent.
- Trial name
- NCT07876336
- Testing
- Clopidogrel
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- October 6 University
Coronary Artery Disease
Safety and Efficacy of CAG and PCI Via Distal Transradial Access in Patients With Small Vessels
Randomized controlled trial of adaptive design for the safety and efficacy of coronary angiography and percutaneous coronary intervention via distal transradial access using a 6-French Glidesheath Slender in patients with small…
- Trial name
- DISTAL-SV (NCT07410364)
- Testing
- Performing coronary angiography and percutaneous coronary intervention via the distal transradial access in patients with small vessels (DRA < 2.0 mm) using a 6-Fr Glidesheath Slender sheath., Performing coronary interventional procedures via the distal radial artery in patients with small vessels ( DRA diameter < 2.0 mm ) using a 6-Fr Conventional sheath.
- Where
- 2 sites in China
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- Cai gaojun, MD
Shock, Cardiogenic
Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock
Outcome of patients with myocardial infarction complicated with cardiogenic shock is very poor. Although early mechanical revascularization has been demonstrated superior to conservative medical treatment, mortality range remains…
- Trial name
- NCT00420030
- Testing
- Abciximab
- Where
- Czechia
- Volunteers
- 80 people
- Sponsor
- Charles University, Czech Republic
Heparin-Induced Thrombocytopenia
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
Several clinical studies in Western countries have revealed that the prevalence of HIT is 0.5 to 5%, varying depending on the clinical setting.
- Trial name
- NCT00198575
- Where
- 13 sites in Japan
- Volunteers
- 1,500 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Heart Transplant Failure and Rejection, Coronary Artery Disease
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
This is a retrospective, multicenter, study including patients undergone to one or more percutaneous revascularization after OHT.
- Trial name
- PCI-HOPE (NCT03538509)
- Testing
- PCI and implantation drug eluting stent or bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fabrizio D'Ascenzo
STEMI
Predictors of In-hospital and Short-term Clinical Outcomes in STEMI Patients Undergoing Primary PCI
The study aims to assess the culprit-SYNTAX score and no-reflow PIANO scores as possible predictors of in-hospital and short-term outcomes among patients with STEMI undergoing primary PCI
- Trial name
- NCT06123793
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Assiut University
Acute Myocardial Infarction, Cardiogenic Shock
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Multicenter, international, randomized, placebo-controlled, double-blind trial comparing intravenous cangrelor and crushed oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock…
- Trial name
- DAPT-SHOCK-AMI (NCT03551964)
- Testing
- Cangrelor, Ticagrelor
- Where
- 29 sites in Czechia, France and 3 more
- Volunteers
- 605 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Myocardial Infarction
Myocardial Protection of Exenatide in AMI
Experimental evidence suggests exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in various conditions.
- Trial name
- EMPIRE (NCT01580514)
- Testing
- exenatide BYETTA® (Amylin-Lilly), Saline
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Kyunghee University Medical Center